Fenfluramine hydrochloride treatment of parkinsonism.
The oral administration of fenfluramine hydrochloride, which acts centrally to augment serotonin-mediated synaptic function, did not alter extrapyramidal signs in either untreated or levodopa-treated parkinsolian patients. These results support the contention that biochemical indices of serotonergic dysfunction in Parkinson disease do not reflect a critical role for serotonin-containing neural systems in the pathophysiology of parkinsonism and that serotonin-active drugs afford no significant therapeutic benefit to patients with this disorder.
D000368:Aged; D004341:Drug Evaluation; D005260:Female; D005277:Fenfluramine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism
D005277:Fenfluramine; D012701:Serotonin